In late December 2021, five new in-vitro diagnostics tests, including one test for COVID-19 spike protein antibodies determination, were added to the Laboratory Test Nomenclature (Laboratoriotutkimusnimikkeistö) in Finland.
The newly introduced tests include:
- 6598 Copper;
- 6599 COVID-19 coronavirus disease, spike protein, antibodies;
- 6600 Hemoglobin, electrophoresis, from blood;
- 6601 Fentanyl, confirmation;
- 6602 Very extensive histological examination or multi-tissue preparation.
The full details in Finnish can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.